Gilead Gains 2.77% as Investors Look Toward Earnings
Shares outpaced major US indexes in the latest session, while consensus estimates point to lower quarterly earnings and slightly higher revenue.
Key takeaways
- Gilead closed at $151.17, up 2.77% in the latest session.
- Consensus estimates call for quarterly EPS of $2.14 and revenue of $7.81 billion.
Gilead Sciences shares rose 2.77% to $151.17 in the latest session, outpacing the S&P 500’s 0.6% gain. The Dow added 0.83%, and the Nasdaq rose 0.64%.
Investors are watching for the company’s upcoming earnings report. Consensus estimates cited by Zacks project earnings of $2.14 per share, down 13.36% from the same quarter a year earlier, and revenue of $7.81 billion, up 0.51%.
Over the past month, Gilead shares gained 1.58%, compared with a 1.97% decline for the Medical sector and a 1.34% rise for the S&P 500. Zacks said its consensus estimate for Gilead’s quarterly earnings per share had increased 0.57% over the past month.
This article was produced with the help of AI technology. Source: Yahoo Finance
